Insulin

Your fasting insulin can be doing the heavy lifting for years while your glucose and HbA1c still look fine. That mismatch is the point of measuring it. When your cells stop responding to insulin as well as they used to, your pancreas quietly pumps out more to keep blood sugar in range, and that hidden effort is what a fasting insulin number captures.

By the time standard glucose testing flags a problem, this compensation has often been running for years. Insulin gives you a look at metabolic strain earlier in the process, and it helps explain why two people with identical glucose readings can have very different underlying biology. Worth knowing up front: the American Diabetes Association's laboratory guidelines do not currently recommend routine insulin testing for most people with or at risk of diabetes, so this is best used as a complementary marker in the context of a broader metabolic picture rather than a standalone diagnostic.

What Insulin Actually Does

Insulin is a small protein hormone made and released by cells in your pancreas called beta cells. After you eat, it acts as the key that lets glucose move from your bloodstream into muscle, fat, and liver cells for storage or fuel. It also tells your liver to stop making new glucose and helps your body store fat and build proteins.

Fasting insulin, measured after an overnight fast, reflects the baseline output your pancreas is producing just to keep resting blood sugar steady. In someone whose cells respond well to insulin, that baseline is low. In someone whose cells resist insulin's signal, the pancreas has to secrete more to get the same effect, which shows up as a higher fasting number.

Type 2 Diabetes and Prediabetes

Insulin resistance is often detectable before blood sugar starts to drift. Your pancreas compensates by making more insulin, and only when that compensation begins to fail does fasting glucose creep up and eventually HbA1c follow. Tracking fasting insulin gives you a window into this earlier stage of the process. That said, current reviews frame insulin resistance and beta-cell dysfunction as evolving in parallel rather than in a strictly sequential order, so insulin is best interpreted alongside glucose and HbA1c rather than as a standalone precursor.

Higher fasting insulin is associated with obesity, prediabetes, type 2 diabetes, and metabolic syndrome, and the mechanism is usually insulin resistance driving compensatory overproduction. On the other end, very low insulin points toward beta-cell failure and is characteristic of type 1 diabetes and advanced type 2 diabetes, where the pancreas can no longer produce enough.

Heart Attack and Stroke Risk

Elevated fasting insulin and insulin resistance predict worse cardiovascular outcomes across several conditions. In one study of patients with diabetes and high-risk vascular disease, each rise in log-transformed fasting insulin was tied to about a 36% higher risk of major cardiovascular events, driven mostly by the need for future artery-opening procedures. A meta-analysis of prospective cohort studies found that people in the highest quantile of fasting insulin had a 50% higher risk of coronary heart disease and a 63% higher risk of hypertension compared with the lowest, with no significant association with stroke incidence itself.

Insulin resistance is also linked to worse recovery after a stroke has already happened. People in the highest fifth of a common insulin resistance score had roughly twice the odds of poor three-month functional recovery compared with those in the lowest fifth. In a single Japanese cohort of patients with heart failure with preserved pumping function, insulin resistance was associated with nearly double the risk of death or hospitalization, though this specific finding has not yet been replicated in broader populations.

A Counterintuitive Finding Worth Understanding

Here is where the story turns subtle. Randomized trials of insulin therapy in type 2 diabetes have not shown that treating patients with basal insulin raises their risk of heart attack, stroke, or death. Yet observational studies consistently link higher fasting insulin, insulin resistance, and insulin use with worse outcomes. The resolution is that these findings measure different things. High endogenous insulin from insulin resistance reflects underlying metabolic disease and is the risk signal. Prescribed basal insulin used to treat established diabetes does not carry the same signal in controlled trials. In other words, having your own body pump out extra insulin because your cells resist it is not the same as taking insulin as a medication, and the two should not be confused when you interpret your own result.

PCOS, Fatty Liver, and Metabolic Syndrome

Polycystic ovary syndrome is classified as an endocrine disorder in which insulin resistance may be central to the underlying biology, with roughly 50 to 80% of women with PCOS showing insulin resistance, so fasting insulin often reflects the underlying biology behind irregular cycles and fertility issues. Metabolic syndrome, the clustering of high blood pressure, high triglycerides, low HDL, and abdominal weight gain, is also tightly linked to insulin resistance.

Insulin surrogates like HOMA-IR and the triglyceride-glucose index have been used to identify metabolic syndrome. In one biobank cohort of 7,875 people, the triglyceride-glucose index reached an accuracy of 0.92 for insulin resistance, though other large studies have reported lower accuracies in the 0.69 to 0.83 range, so performance depends on the population and reference standard. Fasting insulin plus fasting glucose gives you HOMA-IR, one of the most widely used tools for spotting metabolic strain early.

Why One Reading Is Not Enough

A single fasting insulin value tells you something, but the trend over time tells you far more. Insulin secretion follows a circadian pattern with a nocturnal peak, insulin sensitivity varies through the day, and even sleep-wake regularity affects the number. A single reading captures one snapshot of a moving system.

There is also real analytical variability. Different commercial insulin assays disagree substantially. Across commercial methods, between-assay coefficients of variation have been reported to range from about 12% to 66%, and between-laboratory variability across 94 labs ranged from 8.4% to 64.3%. Practically, that means you should keep the same lab and assay, the same fasting status, and ideally the same time of day when tracking your insulin. Small changes on different platforms may reflect the platform, not you.

A reasonable cadence is to get a baseline, retest in 3 to 6 months if you are making lifestyle changes or starting a new medication, and then at least annually. If your number is borderline or unexpected, repeat the test before making decisions. What you want to see is direction of travel across several years, not a single value in isolation.

When Results Can Be Misleading

Several factors can distort a single fasting insulin reading without reflecting your true metabolic health.

• Kidney function: your kidneys clear roughly 25% of daily insulin, and reduced kidney function can raise measured insulin even when your pancreas is behaving normally. In critically ill patients with acute kidney injury, fasting insulin was significantly higher than in those without AKI.
• Recent acute illness or hospitalization: stress hormones and inflammation can spike insulin resistance for days to weeks, temporarily driving up the number.
• Assay differences: switching labs or platforms can shift your result by more than the change your body is actually going through. Different assays are not interchangeable, and only one method has fully agreed with reference mass spectrometry in recent comparisons.
• Certain medications: glucocorticoids frequently trigger hyperglycemia or new-onset diabetes, with reported incidence roughly 18 to 32% for glucocorticoid-induced diabetes in outpatients on high doses and 56 to 86% for hyperglycemia in hospitalized patients, through reduced insulin sensitivity that can push fasting insulin up. Second-generation antipsychotics, thiazide diuretics, some beta-blockers, and higher-dose statins can also alter the glucose-insulin balance as a side effect, not by treating anything related to diabetes.

What to Do With an Unexpected Result

If your fasting insulin comes back higher than expected, the next step is not to panic but to fill in the picture. Pair it with fasting glucose to calculate HOMA-IR, add HbA1c to see whether long-term glucose control is starting to slip, and check triglycerides and HDL, which move with insulin resistance. If several of these are trending the wrong way together, that is a stronger signal than any single number.

A C-peptide test can help clarify whether your pancreas is over- or under-producing insulin, especially in ambiguous cases. If your result is very high alongside frank hyperglycemia, or very low with unexplained symptoms of low blood sugar, that is a reason to involve a clinician who focuses on metabolic health or endocrinology. For most people with a moderately elevated reading and otherwise normal labs, the pathway is to repeat testing, address lifestyle drivers, and monitor the trend rather than treat a single value.